LPCN Stock Catalyst: Lipocine Inc. Receives Health Canada Approval for TLANDO®

Oct 7, 2026 · 6:28am ET

Approval for testosterone replacement therapy.

Max move

+87.4%

High of day $3.93

Sparker timei

6:28am ET

LPCN · Oct 7, 2026

CATALYST DATE · 1-MINUTE BARS

Catalyst Summary

Lipocine Inc. (LPCN) announced on October 7, 2026, that Health Canada has granted approval for TLANDO®, its testosterone replacement therapy. The approval was disclosed in an 8-K filing.

TLANDO® is now approved in Canada for the treatment of male hypogonadism.

As of the latest available data, Lipocine Inc. has a free float of 7,530,300 shares.

This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.

Real-time alerts

Get notified the next time LPCN sparks.

Download Sniper App →

Catch the next LPCN-style move in real time.

Day Trader Sniper alerts you the moment a setup like this triggers: premarket, open, or intraday.

Watch demo Download Free →